Eye cancer, also known as ocular cancer, refers to a group of rare but potentially serious malignancies that develop within the eye or its surrounding structures. While uncommon, eye cancer presents unique clinical challenges due to its impact on vision, complex anatomy and potential for metastasis.
For healthcare professionals, sponsors and clinical research organisations (CROs), ocular oncology represents a highly specialised area where early detection, precise diagnosis and innovative therapies are critical to improving patient outcomes. This is where specialised support such as clinical trial management services, becomes essential in delivering complex oncology studies.
What is Eye Cancer?
Eye cancer occurs when abnormal cells within the eye begin to grow and divide uncontrollably, forming a tumour. These tumours may be:
- Benign (non-cancerous) – do not spread
- Malignant (cancerous) – can invade nearby tissues and metastasise
Primary ocular cancer originates in the eye itself, whereas secondary eye cancer occurs when cancer spreads from another part of the body, such as the breast or lung.
A key clinical concern is metastasis. In many cases of ocular cancer, particularly uveal melanoma, cancer cells can spread via the bloodstream, most commonly to the liver. This significantly impacts prognosis and treatment strategy.
Types of Ocular Cancer
Ocular cancer is classified based on where it develops and the type of cells involved. Understanding these distinctions is essential for diagnosis, treatment selection and clinical trial design. Particularly in oncology, including rare indications, specialist expertise is critical for effective study delivery.
Intraocular Melanoma
Intraocular melanoma is the most common form of eye cancer in adults. It develops from melanocytes, the pigment-producing cells found within the eye. Most cases are classified as uveal melanoma, meaning they arise in the uvea, the middle layer of the eye.
This includes:
- Iris melanoma – forms in the visible, coloured part of the eye and is often detected earlier
- Ciliary body melanoma – develops behind the iris and may go unnoticed until symptoms occur
- Choroidal melanoma – the most common subtype, occurring in the vascular layer that supplies the retina
Retinoblastoma
Retinoblastoma is a rare but significant form of ocular cancer that primarily affects children under the age of five. It develops in the retina and is strongly associated with genetic mutations. Early diagnosis is critical, as prompt treatment can be life-saving and may preserve vision.
Ocular Lymphoma
Ocular lymphoma is a subtype of non-Hodgkin lymphoma that affects the eye, often involving lymphocytes. It may occur alongside central nervous system lymphoma, making diagnosis and management more complex.
Orbital and Adnexal Cancers
These cancers develop in tissues surrounding the eye, including the eyelids, tear glands and muscles.
They include:
- Basal cell carcinoma
- Squamous cell carcinoma
- Rhabdomyosarcoma
Although not always originating within the eyeball, they are still considered part of the broader ocular oncology landscape.
How Common is Eye Cancer?
Eye cancer is considered rare. Incidence rates are low compared to other oncology indications, making it a challenging area for clinical trials due to limited patient populations. This makes ocular cancer well-suited to rare and ultra-rare disease trial approaches, where patient recruitment and global coordination are key challenges. However, this rarity also highlights the importance of specialised research, global trial access and patient recruitment strategies in ocular oncology.
Symptoms of Eye Cancer
One of the key challenges in diagnosing eye cancer is that symptoms are often absent in the early stages. Many cases are identified during routine eye examinations. When symptoms do occur, they may include:
- Blurred or partial vision loss
- Flashes of light or floaters
- A dark or growing spot on the iris
- Eye irritation or redness that persists
- A visible lump on the eyelid or eye surface
- Changes in eye position or movement
These symptoms are not specific to ocular cancer and may be associated with more common eye conditions, which is why clinical evaluation is essential.
Causes and Risk Factors of Eye Cancer
Eye cancer develops when genetic mutations disrupt normal cell regulation, causing cells to grow uncontrollably and form tumours.
As the disease progresses, cancer cells may spread through the bloodstream or lymphatic system, a process known as metastasis. In ocular cancer, metastasis most commonly affects the liver and is a major determinant of patient outcomes. The exact causes of these mutations are still being studied, but several risk factors have been identified.
Key Risk Factors
- Age – Most cases occur in adults over 50, although retinoblastoma primarily affects young children
- Eye colour – Individuals with blue or green eyes are at increased risk
- Skin type – Fair skin is associated with higher susceptibility
- Genetic predisposition – Conditions such as BAP1 tumour predisposition syndrome increase risk
- UV exposure – There is ongoing research into the role of ultraviolet light in ocular melanoma
Understanding these risk factors is important in patient stratification for clinical studies.
Diagnosis of Ocular Cancer
Accurate and early diagnosis is essential for improving outcomes in eye cancer. Diagnosis typically involves a combination of clinical examination, imaging and, in some cases, biopsy.
Eye Examination
Specialists such as ophthalmologists or ocular oncologists use tools including:
- Ophthalmoscope – to examine the back of the eye
- Slit-lamp microscope – to assess detailed eye structures
Imaging Techniques
Imaging plays a central role in diagnosis and staging:
- Ultrasound – to assess tumour size and location
- Fluorescein angiography – to evaluate blood flow in the eye
- MRI or CT scans – to detect spread beyond the eye
Biopsy and Molecular Analysis
While not always required, a biopsy can provide valuable insights into tumour biology, including genetic mutations. This information is increasingly important in:
- Prognostic assessment
- Treatment selection
- Eligibility for targeted therapies and clinical trials
Treatment Options for Eye Cancer
Treatment for eye cancer (ocular cancer) depends on the type of tumour, its size and location, and whether it has spread beyond the eye (metastasised).
Clinicians also consider factors such as tumour growth rate, the patient’s overall health, and the potential impact on vision and quality of life. In some cases, particularly with small or slow-growing tumours, active surveillance may be appropriate before treatment begins. Treatment approaches are typically divided into local therapies (targeting the eye) and systemic therapies (for advanced or metastatic disease).
Radiation Therapy
Radiation therapy is a primary treatment for many ocular cancers, particularly intraocular melanoma, aiming to destroy cancer cells while preserving the eye.
- Brachytherapy – a radioactive plaque is placed near the tumour to deliver targeted radiation
- External Beam Radiation Therapy (EBRT) – radiation is directed at the tumour from outside the body, using highly precise techniques
Surgery
Surgery may be required depending on tumour size and progression.
- Local tumour resection – removal of small tumours while preserving the eye
- Enucleation – removal of the eye in advanced cases where vision cannot be saved
- Orbital surgery – used if cancer has spread to the surrounding tissues
Laser Therapy
Laser treatments are typically used for small tumours or alongside other therapies.
- Transpupillary thermotherapy (TTT) – uses heat to destroy cancer cells and may reduce recurrence risk
Systemic Treatments
Systemic therapies are used when cancer has spread or carries a high risk of metastasis.
- Immunotherapy – stimulates the immune system to target cancer cells
- Targeted therapy – acts on specific genetic mutations
- Chemotherapy – less commonly used, but may be required in certain cases
These innovative therapies are a key focus of early-phase and first-in-human studies, where precise dose evaluation and safety monitoring are critical.
Treatment Decision-Making
Treatment selection requires a multidisciplinary approach and is guided by tumour characteristics, staging and, increasingly, genetic profiling. These factors are also critical in determining clinical trial eligibility and access to emerging therapies.
Prognosis and Survival
Prognosis in eye cancer (ocular cancer) varies significantly depending on several clinical factors, including tumour size, location, stage at diagnosis, and whether the disease has metastasised.
Early-stage ocular cancer, particularly when confined to the eye, can often be managed effectively, with treatments focused on tumour control and, where possible, preservation of vision. However, once the cancer spreads beyond the eye, prognosis becomes more complex.
Metastatic ocular cancer, most commonly involving the liver, remains challenging to treat and is associated with reduced survival rates. As a result, early diagnosis and risk stratification are critical in improving long-term outcomes.
The Importance of Early Detection
A major challenge in eye cancer is that many patients are asymptomatic in the early stages, meaning the disease is often detected incidentally during routine eye examinations.
Early detection is crucial because it:
- Increases the likelihood of successful, eye-preserving treatment
- Reduces the risk of metastatic spread
- Enables earlier clinical intervention and monitoring
- Expands access to clinical trials and emerging therapies
Regular eye examinations, therefore, play a vital role not only in diagnosis but also in improving prognosis and broadening treatment options.
Advancing Research in Ocular Cancer
Ocular cancer remains an area of significant unmet medical need, driven by its rarity, biological complexity and limited treatment options in advanced disease.
Current research is focused on improving both outcomes and understanding of the disease through:
- Targeted therapies informed by genetic and molecular profiling
- Immunotherapies designed to enhance anti-tumour response
- Advanced imaging and diagnostic tools for earlier and more accurate detection
- Strategies to predict and prevent metastasis, particularly in high-risk patients
Given the small patient populations involved, progress in ocular oncology depends heavily on well-designed clinical trials and global collaboration.
Clinical research organisations (CROs) play a central role in this ecosystem by supporting study design, patient recruitment, regulatory navigation and international trial delivery, helping to accelerate the development of new therapies.
Recent Advances in Eye Cancer Research
Ocular cancer remains an active area of research, particularly for advanced disease, where treatment options have historically been limited. Recent studies have shown promising progress in immunotherapy for uveal melanoma, helping improve outcomes in some patients with metastatic disease.
Advances in genetic profiling are also enabling more personalised treatment approaches, while improvements in imaging and biomarker development are supporting earlier detection and more accurate monitoring.
Given the rarity of eye cancer, these developments rely heavily on specialised clinical trials and global collaboration, highlighting the importance of expert-led research and trial delivery.
Final Note
Eye cancer, or ocular cancer, is a rare and complex condition that requires specialised diagnosis, multidisciplinary care and ongoing research. While outcomes have improved, particularly with earlier detection, significant challenges remain, especially in the treatment of metastatic disease.
Continued investment in clinical research is essential to advance understanding, develop more effective therapies and improve patient outcomes. For organisations involved in clinical development, ocular oncology represents a critical opportunity to address an underserved area of cancer care and drive meaningful innovation